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Background: Calcification is an independent predictor of mortality in calcific aortic valve disease (CAVD). The aim
of this study was to evaluate the use of non-invasive, non-ionizing echocardiographic calibrated integrated
backscatter (cIB) for monitoring progression and subsequent regression of aortic valvular calcifications in a rat
model of reversible renal failure with CAVD, compared to histology.
Methods: 28 male Wistar rats were prospectively followed during 21 weeks. Group 1 (N=14) was fed with a 0.5%
adenine diet for 9 weeks to induce renal failure and CAVD. Group 2 (N=14) received a standard diet. At week 9, six
animals of each group were killed. The remaining animals of group 1 (N=8) and group 2 (N=8) were kept on a
standard diet for an additional 12 weeks. cIB of the aortic valve was calculated at baseline, 9 and 21 weeks,
followed by measurement of the calcified area (Ca Area) on histology.
Results: At week 9, cIB values and Ca Area of the aortic valve were significantly increased in the adenine-fed rats
compared to baseline and controls. After 12 weeks of adenine diet cessation, cIB values and Ca Area of group 1
decreased compared to week 9, while there was no longer a significant difference compared to age-matched
controls of group 2.
Conclusions: cIB is a non-invasive tool allowing quantitative monitoring of CAVD progression and regression in a
rat model of reversible renal failure, as validated by comparison with histology. This technique might become
useful for assessing CAVD during targeted therapy.
Keywords: Aortic valve calcifications, Calcific aortic valve disease, Echocardiography, Integrated backscatter, Renal
failure, Small animalBackground
Calcific aortic valve disease (CAVD) is currently the most
frequent valvular heart disease in the western world [1].
The extent of calcification has been shown to be an inde-
pendent predictor of morbidity and mortality in CAVD
[2,3]. Medical therapies to attenuate or even prevent pro-
gression of CAVD are being increasingly investigated [4].* Correspondence: broosens@gmail.com
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reproduction in any medium, provided the orEvaluation of medication-induced reversibility of valvular
calcifications with non-invasive imaging modalities is
promising. Computed tomography (CT) is considered as
the reference technique for the quantification and follow-
up of calcifications in patients at increased cardiovascular
risk [5]. However, cardiac CT raises concerns about irra-
diation, which may limit repetitive scanning [6]. Recently,
we have validated the non-invasive and non-ionizing tech-
nique of echocardiographic integrated backscatter (IB) for
the quantification of both normal, age-related and vitamin
D-induced aortic valve calcifications in rats [7,8]. Animal
models such as rats are increasingly used to study the
pathophysiology of CAVD and to test potential medicall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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might be of interest to monitor the progression and regres-
sion of aortic valve calcifications in animals and humans.
Rats fed with an adenine and high phosphate diet are a
validated model of renal failure and secondary hyperpara-
thyroidism with subsequent CAVD. A previous study has
shown that discontinuation of such a diet led to progressive
recovery of the renal function and spontaneous regression
of aortic valve calcifications [10].
The aim of the present study was to evaluate the use of
echocardiographic IB as a non-invasive and non-ionizing
imaging technique for monitoring progression and subse-
quent regression of aortic valvular calcifications in a vali-
dated rat model of reversible renal failure with CAVD,
compared to histology.Methods
Study design
Twenty-eight male Wistar Unilever rats (Harlan, The
Netherlands, 7 weeks old) were prospectively divided in
two groups and followed for 21 weeks. Group 1 (N=14)
was fed with a 0.5% adenine, 1.5% phosphorus, 0.6% cal-
cium diet (ssniff Spezialdiaten GmbH, Soest, Germany) for
9 weeks to induce renal failure. Group 2 (N=14) of control
rats was fed with a standard diet (rat maintenance diet,
SAFE, France). At week 9, six animals of each group were
killed for histopathological analysis. For the regression
phase, all remaining animals of group 1 (N=8) and group 2
(N=8) were kept on a standard diet and followed for an
additional 12 weeks. At baseline, week 9 and week 21,
echocardiography was performed and a blood sample was
taken. At the end of the study the remaining animals were
killed with 120 mg/Kg sodium pentobarbital intravenously.
The hearts were excised within 30 minutes of death and
fixed in neutral buffered formalin 4% for 24 hours, fol-
lowed by histology. The observers were blinded to the
group identity for all analysis. The Ethics Committee for
animal studies of the Vrije Universiteit Brussel approved
the study protocol. Guidelines of the National Institute of
Health’s Guide for the Care and Use of Laboratory Ani-
mals (NIH publication 86–23, revised 1985) were followed.Animal handling
During the whole study, all rats were housed in stainless
steel cages with sawdust bedding. They were kept at a
twelve hour day/night cycle, an average room temperature
of 24°C and a relative humidity of 50%. Food and water
were provided ad libitum.
Physiological parameters
Body weight was determined weekly. Physical condition
of the animals was assessed daily.Echocardiography
Rats were anaesthetized with 5% isoflurane gas (S.A. Abbott
N.V., Ottignies, Belgium). Subsequently, the animals were
put under continuous isoflurane gas (2.5%) anaesthesia with
2L O2/min as carrier gas. The anterior chest wall was
shaved and the rat was placed in left lateral decubitus on a
wooden bench in order to obtain optimal image quality and
views, as previously described [11]. Electrocardiogram elec-
trodes were fixed on the paws. A 10 MHz neonatal probe
(10S) operated a 10 MHz was used, connected to a Vivid 7
Pro system (GE Medical Systems, Milwaukee, WI, USA).
Left ventricular and aortic valve function
As previously described [11], left ventricular (LV)
volumes were calculated from the M-mode tracings in
the short-axis view (papillary muscle level, average of 3
cycles) using an ellipsoid model: Pi × D3/3 (where D is
the diameter of the ventricle in the short-axis view). LV
ejection fraction (EF) was calculated from the LV end-
diastolic volume (LVEDV) and LV end-systolic volume
(LVESV): LVEF=([(LVEDV – LVESV)/LVEDV] × 100).
Heart rate was determined from the R-R interval on the
electrocardiogram. Cardiac output (CO) was calculated as
stroke volume × heart rate, with stroke volume deter-
mined from the LV EDV - LV ESV. The peak diastolic
early (E) and late (A) velocities were assessed from the mi-
tral valve pulsed wave Doppler inflow pattern in the apical
4-chamber view. The deceleration time (Dec Time) was
measured. The parasternal long axis view was used to
measure the diameter of the LV outflow tract (LVOT).
The aortic valve (AV) area was calculated using the con-
tinuity equation: [LVOT (TVI) × LVOT area] / Aortic
(TVI). Mean and peak transaortic valve pressure gradients
(Aortic Mean PG, Aortic Peak PG) were measured in the
apical 5-chamber view.
Integrated backscatter analysis
IB of tissue ultrasound reflectivity, measured in decibels
(dB), was used for the quantification of aortic valve calcifi-
cations [8]. IB is the integrated average power of the
squared radiofrequency component of the reflected back-
scatter signal from a region of interest (ROI) within the
tissue [12]. Two-dimensional standard transthoracic para-
sternal short- and long-axis ultrasound images were
obtained at a constant angle of insonification in all rats.
Control settings such as image zoom, focus position,
frame rate, lateral- and time-gain compensation were kept
constant for every measurement to obtain uniform bright-
ness and to facilitate reproducible sampling of backscatter
values [13]. IB values were acquired and averaged over 3
cardiac cycles off-line with a tissue quantification analysis
package (Echopac 110.0.0 (BT10), GE Vingmed) by pla-
cing fifteen 1×1-mm circle-shaped sample volumes (ROIs)
on the aortic valve in all images. Moreover, global ROIs I
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pectively the short- and long-axis. The positions of the
ROIs were within the same region for all animals and du-
ring all cardiac cycles. Blood pools (BP): BP1 of the atrial
cavity in the short-axis, BP2 of the LV outflow tract in the
long-axis. Calibration of the integrated backscatter values
was done to compensate for the attenuation of the back-
scatter signal due to intervening structures between the
skin surface and the ROIs [14]. Calibrated IB (cIB) was
determined by subtracting IB values from the tissue with
the blood pool IB values adjacent to the tissue (cIB value
(ROI X) = [IB value (ROI X) – IB value (ROI BPX)]). An
increase in cIB values reflects an increase in echogenicity.
Mean cIB values for each structure were calculated as fol-
lows: cIB value (ROIAVSA (aortic valve, short-axis)) = Mean
cIB value (ROI 1 to 10); cIB value (ROIAVLA (aortic valve,
long-axis)) = Mean cIB value (ROI 11 to 15); cIB value
(ROIAVTOT (aortic valve, total)) = Mean cIB value (ROIAVSA,
ROIAVLA); cIB value (ROIAVGLOB (aortic valve, global)) =
Mean cIB value (ROI I, II) [8].
Histopathology
The hearts were cut in an axial plane (from base to apex)
and embedded in paraffin. Nine ranges of sections were
made from each paraffin embedded heart, with approxi-
mately 50 μm between each range in order to visualize a
maximum amount of tissue. Slices of 4–6 μm thick were
stained with classic haematoxylin-eosin and Von Kossa.
Experienced pathologists performed tissue analysis with a
PC digital image camera (Digital Sight DS-5M, Nikon
Corp, Japan) mounted on an Axiolab Zeiss light micro-
scope (Carl Zeiss Corp, Germany). The NIH Image pro-
gram (Image-J 1.47a, National Institutes of Health,
Bethesda, MD, USA) was used to calculate the aortic valve
calcified area (Ca Area, mm2) for each rat, by summation
of areas of deposits in the most calcified slice. The pro-
gram was calibrated with a graduated slice.
Biochemistry
Blood samples were acquired from a tail vein in all rats
before echocardiography. Plasma was analyzed for cre-
atinine, blood urea nitrogen (BUN), total calcium (Ca),
phosphorus (P), alkaline phosphate (AP) and osteocalcin
by using reagent kits according to the manufacturer’s
instructions. The calcium × phosphorus (Ca × P) prod-
uct was calculated.
Statistical analysis
Data are expressed as mean ± standard error of the
mean. Variables were tested for normality of distribution
and homogeneity of variance by means of the Shapiro-
Wilk and Levene tests. Comparisons between groups
were performed by using the unpaired and paired Stu-
dent t-test. The Mann–Whitney U and Wilcoxon testwere used for variables approximating normality of dis-
tribution. Study variability and correlations between con-
tinuous variables were evaluated by means of the
Pearson correlation coefficient. All p values were calcu-
lated two-tailed. A p value < 0.05 was considered signifi-
cant. Statistical analysis was done with IBM SPSS




At baseline there was no significant difference in mean
body weight between groups (group 1: 293 ± 5 g; group 2:
295 ± 5 g; p = 0.775). At week 9, mean body weight signifi-
cantly decreased in the adenine-fed group 1 (252 ± 11 g)
compared to control group 2 (468 ± 7 g; p < 0.001). After
adenine-diet cessation, animals from group 1 regained
weight (week 21, group 1: 481 ± 18 g; group 2: 560 ± 13 g;
p = 0.003).
Echocardiography
Left ventricular and aortic valve function
There were no significant differences between groups in
LV and aortic valve parameters at baseline. In the
adenine-fed group 1, there was a significant decrease in
EF, CO and transvalvular PG at week 9 compared to
baseline and group 2. After adenine-diet cessation, the
EF, CO and PG recovered by week 21 in group 1. During
the study course there was no significant difference in
LV diastolic function (E/A, Dec Time) and aortic valve
area between groups (Table 1).
Integrated backscatter analysis of echocardiography
There was a significant correlation between the global
cIB values (ROIAVGLOB) and the mean cIB values
(ROIAVTOT) of the aortic valve (Pearson r = 0.83;
p < 0.001). At baseline, there were no significant differ-
ences in cIB values between groups. After 9 weeks, the
cIB values of the aortic valve were significantly increased
in the adenine-fed group 1 compared to baseline and con-
trol group 2. After adenine diet-cessation at the end of the
study, the cIB values of group 1 decreased compared to
week 9, and there was no more significant difference com-
pared to controls of the same age (Table 2, Figure 1).
There was a significant intra- and inter-observer reprodu-
cibility of cIB values for ROIAVGLOB (respectively Pearson
r = 0.736; p = 0.037; and Pearson r = 0.676; p = 0.032) and
ROIAVTOT (respectively Pearson r = 0.725; p = 0.042; and
Pearson r = 0.652; p = 0.041).
Histology
At week 9, the Ca Area of the aortic valve was signifi-
cantly higher in the adenine-fed group 1 compared to
control group 2. At the end of the study, the Ca Area of
Table 1 Echocardiographic evaluation for each group















Adenine 0.5% Controls Adenine 0.5% Controls Adenine 0.5% Controls
EF (%) 83 ± 2 84 ± 1 0.690 67 ± 3 ** 75 ± 1 ** 0.013 78 ± 1 *# 74 ± 3 * 0.328
CO (ml/min) 171 ± 11 163 ± 11 0.616 95 ± 6 ** 185 ± 6 * < 0.001 214 ± 18 # 207 ± 7 0.738
E/A 1.72 ± 0.18 1.61 ± 0.07 0.970 1.53 ± 0.06 1.52 ± 0.05 0.881 1.48 ± 0.09 1.51 ± 0.07 0.787
Dec time (ms) 44 ± 2 43 ± 1 0.707 45 ± 3 42 ± 2 0.522 47 ± 2 42 ± 2 0.103
AV Area (mm2) 5.1 ± 0.2 4.6 ± 0.3 0.217 5.1 ± 0.4 6.0 ± 0.4 * 0.095 9.5 ± 1.2 *# 8.2 ± 0.7 *# 0.505
Aortic Peak PG
(mmHg)
1.77 ± 0.13 1.64 ± 0.10 0.329 0.97 ± 0.08 * 1.48 ± 0.17 0.020 1.46 ± 0.16 # 1.67 ± 0.12 0.317
Aortic Mean PG
(mmHg)
1.30 ± 0.10 1.17 ± 0.07 0.376 0.68 ± 0.05 * 1.02 ± 0.11 0.008 1.17 ± 0.08 # 1.18 ± 0.09 0.925
Data are represented as means ± SEM. AV, aortic valve; CO, cardiac output; Dec Time, deceleration time; EF, ejection fraction; Gr., group; PG, pressure gradient. *
Vs. Baseline; p < 0.05. ** Vs. Baseline; p < 0.001. # Vs. Week 9; p < 0.05.
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there was no more significant difference compared to
age-matched controls (Table 2, Figure 2). There were
significant correlations between cIB values and the histo-
logical Ca Area for all rats (respectively ROIAVGLOB:
Pearson r = 0.546; p = 0.003; and ROIAVTOT: Pearson
r = 0.487; p = 0.010 ).
Blood Biochemistry
At baseline, there was no significant difference in blood
biochemistry between groups. After 9 weeks, there was a
significant increase in creatinine, BUN, P, and Ca × P in
the adenine-fed group 1 compared to control group 2
and baseline. At week 9, AP and osteocalcin were also
significantly increased in the adenine-fed group 1 com-
pared to control group 2.
After 21 weeks, the renal function slightly recovered in
group 1 after adenine diet discontinuation. There were no
more significant differences between groups for P, Ca ×
P, and AP. However, osteocalcin remained significantly
increased in group 1 compared to group 2 (Table 3).Table 2 Calibrated integrated backscatter (cIB) values and his
Gr 1
Adenin
cIB Baseline (dB) ROIAVTOT 13.4 ±
ROIGLOB 16.9 ±
cIB Week 9(dB) ROIAVTOT 16.4 ±
ROIGLOB 20.7 ±
cIB Week 21 (dB) ROIAVTOT 14.8 ±
ROIGLOB 18.3 ±
Ca Area Week 9 (mm2) 0.076
Ca Area Week 21 (mm2) 0.023 ±
Data are represented as means ± SEM. dB, decibel; Gr., group; ROIAVTOT, region of in
Baseline; p < 0.001. # Vs. Week 9; p = 0.037.Discussion
In the present study, we have shown that echocar-
diographic cIB is a useful tool for the non-invasive,
quantitative monitoring of progression and subsequent
spontaneous regression of aortic valve calcifications in
a rat model of diet-induced renal failure. We validated
this technique by comparison with histology.CAVD and its relationship with renal failure
CAVD accounts for 70% of all valvular heart diseases
and evolves to significant aortic valve stenosis in about
10% of patients. In this population, the outcome is poor
as there is a significant 5-year increased risk of progres-
sion to heart failure or death [15]. Hence, there is a need
for medical treatment of CAVD. However, reversal of
end-stage macrocalcification is deemed difficult [3]. To
date, medical therapies have failed to demonstrate a sig-
nificant effect on advanced valvular calcifications [4]. In
animal studies, only early preventive medical interven-
tions have shown to be of interest [9].tological calcium area (Ca Area) of the aortic valve
Gr 2 p (Gr 1 vs. Gr 2)
e 0.5% Controls
0.4 14.2 ± 0.5 0.259
0.6 16.6 ± 0.6 0.739
0.5 ** 13.3 ± 0.6 0.001
0.5 ** 17.2 ± 0.7 < 0.001
0.8 14.2 ± 0.5 0.531
1.3 18.7 ± 1.0 0.784
± 0.021 0.0 ± 0.0 0.005
0.012 # 0.0 ± 0.0 0.074
terest, aortic valve, total; ROIGLOB, region of interest, aortic valve, global. ** Vs.
Figure 1 Echocardiography of the aortic valve of adenine-fed and control rats. Echocardiography of the aortic valve in the short-axis (SA)
and long-axis (LA) of adenine-fed group 1 and control group 2 rats, at baseline, week 9 and week 21. Arrows indicate valvular calcifications. After
cessation of the adenine-diet in group 1 (after week 9), regression of calcifications is observed.
Figure 2 Histology of the aortic valve of adenine-fed and control rats. Histology of the aortic valve of adenine-fed group 1 and control group
2 rats, at weeks 9 and week 21. Arrows indicate valvular calcifications that are mainly situated in the aortic annulus. After cessation of the adenine-diet
in group 1 (after week 9), regression of calcifications is observed. Scale bar is 500 μm, original magnification at 25 x, haematoxylin-eosin staining.
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Table 3 Blood biochemistry values for each group
Baseline Week 9 Week 21
Gr 1 (N=14) Gr 2 (N=14) p (Gr 1
vs. Gr 2)
Gr 1 (N=14) Gr 2 (N=14) p (Gr 1
vs. Gr 2)
Gr 1 (N=8) Gr 2 (N=8) p (Gr 1
vs. Gr 2)
Adenine 0.5% Controls Adenine 0.5% Controls Adenine 0.5% Controls
Creatinine
(mg/dl)
0.39 ± 0.01 0.42 ± 0.01 0.078 2.33 ± 0.16 * 0.47 ± 0.01 * < 0.001 2.01 ± 0.36 * 0.47 ± 0.01 * < 0.001
BUN (mg/dl) 34.7 ± 1.7 33.2 ± 1.2 0.466 240.6 ± 13.0 * 33.4 ± 1.0 < 0.001 182.2 ± 28.0 * 32.3 ± 1.0 < 0.001
Ca (mg/dl) 10.6 ± 0.1 10.3 ± 0.2 0.478 7.8 ± 0.2 * 10.1 ± 0.1 < 0.001 10.0 ± 0.3 *# 10.7 ± 0.1 # 0.028
P (mg/dl) 6.6 ± 0.3 7.0 ± 0.2 0.322 17.0 ± 0.9 * 5.6 ± 0.3 * < 0.001 6.7 ± 1.2 # 5.0 ± 0.2 * 0.234
Ca x P
(mg2/dl2)
70.0 ± 3.2 72.1 ± 2.9 0.639 132.8 ± 9.2 * 56.4 ± 1.8 * < 0.001 65.4 ± 9.4 # 52.1 ± 1.5 * 0.234
AP (U/L) 315.5 ± 9.8 303.6 ± 13.0 0.473 171.5 ± 6.5 ** 133.1 ± 7.0 ** 0.001 117.5 ± 2.9 **## 115.6 ± 5.6 **## 0.770
Osteocalcin 58.5 ± 2.2 54.2 ± 1.8 0.082 62.1 ± 2.2 19.8 ± 1.4 * < 0.001 75.8 ± 2.5 *# 11.3 ± 0.4 *# < 0.001
Data are represented as means ± SEM. AP, alkaline phosphate; BUN, blood urea nitrogen; Ca, calcium; Ca x P, calcium x phosphorus product; Gr., group; P, phosphorus. *
Vs. Baseline; p < 0.05. ** Vs. Baseline; p < 0.001. # Vs. Week 9; p < 0.05. ## Vs. Week 9; p < 0.001.
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calcifications and CAVD due to secondary hyperpara-
thyroidism and a disturbed mineral metabolism with
increased Ca × P [2]. In chronic kidney disease, approxi-
mately 50% of patients will develop CAVD at an accele-
rated rate, leading to increased morbidity and mortality
[16,17]. Small animal models such as rats have become
increasingly important to study renal failure and CAVD
[9]. Shuvy et al. have previously investigated a rat model
of adenine and high-phosphate diet-induced renal failure
and subsequent CAVD [10]. Interestingly, in this study
discontinuation of the diet led to a progressive recovery
of the renal function after 2 weeks and marked sponta-
neous improvement of the aortic valvular calcifications
after 12 weeks [10]. The observed reversibility of CAVD
might offer an opportunity for the development of new
medical treatments.
Imaging of aortic valve calcifications
Calcification is an independent predictor of morbidity and
mortality in CAVD [2,3]. Quantification of calcifications in
CAVD with in vivo imaging tools could be helpful for the
monitoring of disease progression and potential regression
through medical interventions. Although the reference ap-
proach, the use of cardiac CT is limited due to irradiation
exposure of patients. Repetitive evaluation by cardiac CT
is thus hampered. Conventional echocardiography primar-
ily makes use of specular reflections and Doppler ultra-
sound to investigate valve morphology and function [18].
Aortic valve calcification is rather regarded as a categorical
variable with the current qualitative methodology [19].
However, by analyzing backscatter reflections generated
by the interaction of ultrasound with small tissue struc-
tures, it is possible to quantitatively extract information
related to the valve’s composition [12,20,21]. IB has pre-
viously been extensively validated in the myocardium as asurrogate marker of fibrosis and for the differentiation of
atherosclerotic lesions [22,23]. We have previously shown
that with IB calcific deposits of the aortic valve can be
quantitatively and reproducibly assessed in rats [7,8]. O-
thers have used IB for the quantitative detection of aortic
valve calcifications in vitamin D treated rabbits, which
could be delayed with ramipril [24,25]. Preliminary clinical
studies have demonstrated that higher backscatter scores
are seen in sclerotic compared to non-sclerotic aortic
valves, with a further increase in stenotic valves [26,27].
Backscatter scores of the aortic valve directly correlated
with subjective scoring and with transvalvular pressure
gradients in patients [13].
Integrated backscatter analysis of aortic valve
calcifications
In the present study, we have shown that cIB can detect
a significant progression of CAVD after 9 weeks in rats
with renal failure, compared to baseline and controls of
the same age. Twelve weeks after discontinuation of the
adenine diet, the cIB of the aortic valve returned to
values similar to controls, suggesting a regression of the
calcifications. This confirms the validity of cIB for the
quantitative evaluation of aortic valve calcifications
[7,8,24]. Moreover, it corroborates the findings of Shuvy
et al. in a similar model. In that particular study, quanti-
tative CT was used for assessing CAVD. However, the
amount of calcifications on histology and echocar-
diography were not provided [10]. In our study, there
was a significant correlation between cIB and the histo-
logical Ca Area for the aortic valve. Moreover, there was
a significant inter- and intra-observer reproducibility of
cIB values. Global cIB values (ROIAVGLOB) and mean cIB
values (ROIAVTOT) also correlated significantly. This im-
plies that the global cIB values can be used, potentially
simplifying the technique for daily practice.
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function during adenine feeding in group 1 compared to
controls, associated with a significant increase of P, Ca × P,
AP and osteocalcin. After diet cessation in group 1, P, Ca ×
P and AP normalized at 21 weeks. Interestingly, in our
study there was only a minor improvement of the renal
function after diet cessation in group 1, in contrast to the
complete recovery seen in the study of Shuvy et al. [10].
This could be due to a difference in susceptibility of the
rat strain (Wistar versus Sprague–Dawley). Our results
confirm a previous study by Okada et al., suggesting
irreversible renal failure after 4 weeks of treatment with
adenine (0.75%) [28]. As a regression of CAVD was seen
in spite of the remaining elevated creatinine values, it
seems that the metabolic changes induced by renal failure
and secondary hyperparathyroidism may be the major
mediators of CAVD, rather than renal failure per se [10].
The elevation and subsequent regression of AP might
confirm a role of increased bone turnover with mobilisation
of Ca and P in secondary hyperparathyroidism-associated
CAVD [29]. Osteocalcin levels remained high at the end of
the study in group 1, even 12 weeks after diet cessation.
This calcification inhibitor might be produced by differen-
tiated osteoblast-like cells in the calcifying cardiovascula-
ture in an attempt to further prevent and/or reduce
calcifications [4]. In the adenine-fed group 1, there was a
weight loss as previously described [30], with a reduction in
EF, CO and transvalvular PG on echocardiography. How-
ever, LV performance returned to normal after diet cessa-
tion in group 1.
Future perspectives
Backscatter software is now widely available on recent
echocardiography packages, which makes this tool feasible
for clinical application. In daily practice, cIB may be used
for the detection of early aortic valve calcifications, for the
assessment of disease severity and progression as well as
for evaluating the effectiveness of potential medical inter-
ventions in prospective and longitudinal trials.
Conclusions
Calibrated integrated backscatter is a promising, non-
invasive echocardiographic tool to quantitatively monitor
progression and regression of aortic valve calcifications in
a rat model of diet-induced renal failure, as validated by
comparison with histology. This technique might become
useful for assessing CAVD during targeted therapy.
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